Showing 2641-2650 of 5956 results for "".
- Euclid Systems Launches New Euclid MAX Ortho-K Lenshttps://modernod.com/news/euclid-systems-launches-new-euclid-max-ortho-k-lens/2479200/Euclid Systems announced the United States launch of the overnight orthokeratology lens Euclid MAX. Used in children and adult patients with progressive myopia, but especially children, Ortho-K contact lenses gently reshape the cornea to manage myopia while the patient sleeps. “Euclid MAX
- Johnson & Johnson Vision Announces FDA Approval of Acuvue Abiliti Overnight Therapeutic Lenses for Myopia Managementhttps://modernod.com/news/johnson-johnson-vision-announces-fda-approval-of-acuvue-abiliti-overnight-therapeutic-lenses-for-myopia-management/2479199/Johnson & Johnson Vision Care announced that the FDA has approved Acuvue Abiliti-Overnight Therapeutic Lenses. This is the first and only FDA approved orthokeratology (ortho-k) contact lens for the management of myopia. “The FDA approval of Abiliti Overnight marks an
- Mount Sinai Ophthalmologists Develop New Technique to Assess Progression of Sickle Cell Retinopathyhttps://modernod.com/news/mount-sinai-ophthalmologists-develop-new-technique-to-assess-progression-of-sickle-cell-retinopathy/2479189/Ophthalmologists at New York Eye and Ear Infirmary of Mount Sinai have created a new technique to evaluate patients with sickle cell retinopathy and assess the disease before it progresses and leads to permanent vision loss. Using optical coherence tomography (OCT) angiography, the resear
- Tarsus Pharmaceuticals Initiates Saturn-2 Phase 3 Trial Evaluating the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-initiates-saturn-2-phase-3-trial-evaluating-the-safety-and-efficacy-of-tp-03-for-the-treatment-of-demodex-blepharitis/2479179/Tarsus Pharmaceuticals announced that it has commenced enrollment in Saturn-2, its second pivotal trial evaluating the company’s novel investigational treatment, TP-03, in patients with Demodex blepharitis. Up to 25 million Americans may be affected by Demodex blepharitis, which is caused by an i
- Verana Health: Study Demonstrates Promise of Real-World Data in Ophthalmic Clinical Developmenthttps://modernod.com/news/verana-health-study-demonstrates-promise-of-real-world-data-in-ophthalmic-clinical-development/2479172/Verana Health unveiled research during the 2021 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. In a first-of-its kind study, Verana Health demonstrated that it was able to successfully use
- CooperVision Expands Prescription Options for Biofinity XR Toric Contact Lenseshttps://modernod.com/news/coopervision-expands-prescription-options-for-biofinity-xr-toric-contact-lenses/2479170/CooperVision is introducing a broader range of expanded parameters for its Biofinity XR toric lenses. The addition of sphere powers from ±10.50D to ±20.00D nearly doubles the number of available prescription options specific to this lens, making it easier for eye care professionals to fit patient
- Novartis’ Sandoz Unit Confirms Late-Stage Clinical Development Plans for Proposed Biosimilar Aflibercepthttps://modernod.com/news/novartis-sandoz-unit-confirms-late-stage-clinical-development-plans-for-proposed-biosimilar-aflibercept/2479166/Sandoz, a division of Novartis, announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical phase 3 confirmatory efficacy and safety study, shortly.1 Aflibercept (
- Lineage Cell: OpRegen Clinical Data Continues to Demonstrate Improvements in Patients With Dry AMD With GAhttps://modernod.com/news/lineage-cell-opregen-clinical-data-continues-to-demonstrate-improvements-in-patients-with-dry-amd-with-ga/2479160/Lineage Cell Therapeutics announced that updated interim results from its ongoing, 24-patient phase 1/2a clinical study of its lead product candidate, OpRegen, were reported at the 2021 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2021). OpRegen is an investigational
- Unity Biotechnology Presents Data Demonstrating Improvement in Retinal Vasculature and Function in Preclinical Models of Diabetic Retinopathy Eye Diseaseshttps://modernod.com/news/unity-biotechnology-presents-data-demonstrating-improvement-in-retinal-vasculature-and-function-in-preclinical-models-of-diabetic-retinopathy-eye-diseases/2479156/Unity Biotechnology announced preclinical data demonstrating that UBX1325, a novel senolytic small molecule inhibitor of Bcl-xL, improves retinal vasculature and is differentiated from anti-VEGF agents in preclinical models. Researchers show that inhibition of retinal Bcl-xL by UBX1325 selectivel
- New Alcon Data on Contact Lens, Dry Eye, and Ocular Health to Be Presented at ARVO 2021https://modernod.com/news/new-alcon-data-on-contact-lens-dry-eye-and-ocular-health-to-be-presented-at-arvo-2021/2479151/Alcon will present new data on several of its latest contact lens, dry eye, and ocular health innovations during the Association for Research in Vision and Ophthalmology (ARVO) 2021 virtual meeting taking place May 1-7. Alcon boasts a robust scientific showing at the meeting with nine accepted ab